Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pfizer's other long-term liabilities for the quarter that ended in Mar. 2026 was CHF11,750 Mil.
Pfizer's quarterly other long-term liabilities
increased
from Sep. 2025 (CHF11,519 Mil) to Dec. 2025 (CHF12,401 Mil) but then
declined
from Dec. 2025 (CHF12,401 Mil) to Mar. 2026 (CHF11,750 Mil).
Pfizer's annual other long-term liabilities
declined
from Dec. 2023 (CHF15,202 Mil) to Dec. 2024 (CHF13,242 Mil) and
declined
from Dec. 2024 (CHF13,242 Mil) to Dec. 2025 (CHF12,401 Mil).
Pfizer Other Long-Term Liabilities Related Terms
Pfizer Other Long-Term Liabilities Historical Data
* Premium members only.
The historical data trend for Pfizer's Other Long-Term Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.
What does a Other Long-Term Liabilities of CHF11,750 Mil mean?
Pfizer (XSWX:PFE) has a Other Long-Term Liabilities of CHF11,750 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pfizer and its competitors.
Is Pfizer's Other Long-Term Liabilities too high?
Pfizer's current Other Long-Term Liabilities is CHF11,750 Mil. Overall, Pfizer has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Other Long-Term Liabilities compare to GILD and BMY?
Pfizer's Other Long-Term Liabilities of CHF11,750 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pfizer and its competitors. Pfizer's current Other Long-Term Liabilities is CHF11,750 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (XSWX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is CHF21.24, compared to a current price of CHF20.22 — trading 4.8% below its estimated fair value. The current Other Long-Term Liabilities is CHF11,750 Mil. Pfizer's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Pfizer (XSWX:PFE), the current Other Long-Term Liabilities is CHF11,750 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pfizer (XSWX:PFE) Overvalued in 2026?
Based on GuruFocus' analysis, Pfizer stock appears to be undervalued.
The current stock price of CHF20.22 is trading 4.8% below its estimated GF Value™ of CHF21.24.
GuruFocus considers Pfizer to be Fairly Valued.
Key valuation signals for XSWX:PFE:
Other Long-Term Liabilities: CHF11,750 Mil
GF Value™: CHF21.24 vs. price of CHF20.22 (4.8% below fair value)
No single metric tells the full story. See the XSWX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
72GF Score
Get the complete analysis for XSWX:PFE
Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:PFE has been successfully added to your 
